Literature DB >> 21311184

Effects of mycophenolate mofetil combined with corticosteroids for induction therapy of microscopic polyangiitis.

Fei Han1, Guangyi Liu, Xiaohui Zhang, Xiayu Li, Qiang He, Xuelin He, Qun Li, Suya Wang, Huiping Wang, Jianghua Chen.   

Abstract

AIMS: We prospectively compared the effects of oral mycophenolate mofetil (MMF) or intravenous cyclophosphamide (IVC) combined with corticosteroids for induction therapy of microscopic polyangiitis (MPA) with renal involvement over a follow-up period of 6 months.
METHODS: 41 MPA patients were randomly assigned to either the open-label MMF group or the IVC group. Patients in the MMF group (n = 19) received oral MMF 1.0 g/day (1.5 g/day for patients with a body weight >70 kg) and patients in the IVC group (n = 22) received IVC in monthly pulses of 1.0 g per pulse (0.8 g per pulse for patients with a body weight <50 kg). Both groups received intravenous methylprednisolone 360-500 mg/day for 3 days, followed by oral prednisone 0.6-0.8 mg/kg/day and gradual tapering.
RESULTS: There was no significant difference of estimated glomerular filtration rate (eGFR) level between the IVC and MMF groups at baseline. At 6 months, the eGFR level increased significantly in both groups, but there was no significant difference between the two. Three patients in the IVC group and 1 in the MMF group received maintenance dialysis within 6 months (p = 0.36). The remission rate was 63.6% in the IVC group and 78.9% in the MMF group (p = 0.23).
CONCLUSION: MMF is effective for inducing remission in Chinese MPA patients and may represent an alternative therapy to monthly impulses of IVC.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21311184     DOI: 10.1159/000324364

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  16 in total

Review 1.  Treatment of ANCA-associated vasculitis, where to go?

Authors:  Cees G M Kallenberg
Journal:  Clin Rev Allergy Immunol       Date:  2012-12       Impact factor: 8.667

2.  Long-term outcome of mycophenolate mofetil treatment for patients with microscopic polyangiitis: an observational study in Chinese patients.

Authors:  Yinghua Chen; Erzhi Gao; Liu Yang; Xia Liu; Kang Li; Zhengzhao Liu; Caihong Zeng; Haitao Zhang; Zhihong Liu; Weixin Hu
Journal:  Rheumatol Int       Date:  2016-05-11       Impact factor: 2.631

Review 3.  [Current guidelines on ANCA-associated vasculitides : Common features and differences].

Authors:  B Hellmich
Journal:  Z Rheumatol       Date:  2017-03       Impact factor: 1.372

Review 4.  French recommendations for the management of systemic necrotizing vasculitides (polyarteritis nodosa and ANCA-associated vasculitides).

Authors:  Benjamin Terrier; Raphaël Darbon; Cécile-Audrey Durel; Eric Hachulla; Alexandre Karras; Hélène Maillard; Thomas Papo; Xavier Puechal; Grégory Pugnet; Thomas Quemeneur; Maxime Samson; Camille Taille; Loïc Guillevin
Journal:  Orphanet J Rare Dis       Date:  2020-12-29       Impact factor: 4.123

Review 5.  Why, when and how should immunosuppressive therapy considered in patients with immunoglobulin A nephropathy?

Authors:  F M Rasche; F Keller; W G Rasche; S Schiekofer; A Boldt; U Sack; J Fahnert
Journal:  Clin Exp Immunol       Date:  2016-09-08       Impact factor: 4.330

Review 6.  [S1 guidelines Diagnostics and treatment of ANCA-associated vasculitis].

Authors:  Jan Henrik Schirmer; Peer M Aries; Kirsten de Groot; Bernhard Hellmich; Julia U Holle; Christian Kneitz; Ina Kötter; Peter Lamprecht; Ulf Müller-Ladner; Eva Reinhold-Keller; Christof Specker; Michael Zänker; Frank Moosig
Journal:  Z Rheumatol       Date:  2017-11       Impact factor: 1.372

7.  Mycophenolate Mofetil Versus Cyclophosphamide for the Induction of Remission in Nonlife-Threatening Relapses of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Randomized, Controlled Trial.

Authors:  Janneke Tuin; Patricia M Stassen; Daria I Bogdan; Jan Broekroelofs; Pieter van Paassen; Jan Willem Cohen Tervaert; Jan-Stephan Sanders; Coen A Stegeman
Journal:  Clin J Am Soc Nephrol       Date:  2019-06-28       Impact factor: 8.237

Review 8.  Clinical pharmacokinetics and pharmacodynamics of mycophenolate in patients with autoimmune disease.

Authors:  Azrin N Abd Rahman; Susan E Tett; Christine E Staatz
Journal:  Clin Pharmacokinet       Date:  2013-05       Impact factor: 6.447

9.  Mycophenolate mofetil plus prednisone for inducing remission of Henoch-Schönlein purpura nephritis: a retrospective study.

Authors:  Fei Han; Liang-liang Chen; Ping-ping Ren; Jing-yun Le; Pei-jing Choong; Hong-ju Wang; Ying Xu; Jiang-hua Chen
Journal:  J Zhejiang Univ Sci B       Date:  2015-09       Impact factor: 3.066

10.  Antineutrophil Cytoplasmic Antibody-Associated Vasculitis With Acute Kidney Injury: Short-Term Recovery Predicts Long-Term Outcome.

Authors:  Xiaohan Huang; Liangliang Chen; Lan Lan; Pingping Ren; Anqi Ni; Yanhong Ma; Yaomin Wang; Yilin Zhu; Ying Xu; Jianghua Chen; Fei Han
Journal:  Front Immunol       Date:  2021-07-09       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.